Sanofi-aventis Recalls Eloxatin Injection Due to Manufacturing Issues
Sanofi-aventis is recalling Eloxatin (oxaliplatin) injection vials because the contract manufacturer had significant Good Manufacturing Practice issues.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II. The source text cites CGMP deviations but does not report specific illnesses, injuries, or deaths, fitting the criteria for a moderate severity recall involving potential quality issues without confirmed harm.
Plain-English summary
Sanofi-aventis US, Inc. is recalling 387,738 vials of Eloxatin (oxaliplatin injection) 5 mg/mL, 100 mg, Rx only. The product was distributed nationwide. The recall involves specific lot numbers and expiration dates ranging from February 2012 to January 2014.
The recall was initiated because Eloxatin was manufactured by Ben Venue Laboratories, a contract manufacturer, which was recently inspected by the agency. The inspection revealed significant issues in Good Manufacturing Practices (CGMP Deviations).
Healthcare providers and patients should stop using the affected vials and contact Sanofi-aventis for further instructions. The affected lots include AD21, AD22, AE24, AE25, AF55, AE26, AF03, AF04, AF21, BL19B, CB11B, CB102B, CB12B, CA01B, BH07, BH08, BH09, and CC109B.
The recalled product
- Product
- Eloxatin (OXALIplatin injection) 5 mg/mL injection, 100 mg, Rx only, Mfd. for: sanofi aventis US LLC Bridgewater, NJ 08807, NDC 0024-0591-20
- Manufacturer
- sanofi-aventis US, Inc.
- Category
- Drug — Antineoplastic
- Hazard
- Affected units
- 387,738
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by sanofi-aventis US, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · sanofi-aventis US, Inc.
See all →- ModerateSanofi-Aventis Recalls Diamigo Diabetes App Due to Unintended Global Access
FDA (Devices) · 2013-01-02
- ModerateSanofi Recalls Eloxatin Injection Due to Manufacturing Practice Deviations
FDA (Drugs) · 2012-07-11
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19